Medpace Holdings, Inc.
Medpace Holdings, Inc. (MEDP) is a clinical research organization (CRO) providing drug development services to pharmaceutical and biotech companies, with a direct political signal from a $1,001-$15,000 holding by former President Donald J. Trump in the executive branch disclosure.
BusinessWhat MEDP does
Medpace Holdings, Inc. operates as a clinical research organization (CRO) that provides clinical development services to the biotechnology, pharmaceutical, and medical device industries. Its services include Phase I-IV clinical trial management, regulatory affairs, clinical monitoring, biometrics, and central laboratory operations. Revenue is derived from contract research fees paid by sponsors for these services.
12 months past · 3 months futureMEDP activity timeline
Executive Branch ConflictsMEDP held by Trump-administration officials
Lifetime Government AwardsMEDP federal contracts
MEDP doesn't hold direct federal contracts.
Verified via USASpending.gov: $0 reported in direct prime-contract awards. Companies in this position typically sell federal services indirectly through prime contractors and integrators (e.g., Lockheed Martin, Booz Allen, Microsoft Azure) or through commercial channels that don't appear in USASpending data.
Politicians Trading MEDPMembers of Congress with recent MEDP positions
Congressional TradesWho in Congress is trading MEDP
Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock
Stock awards & option exercises
Bills Affecting MEDPLive legislation impacting this stock
Political ProfileWhere MEDP sits in Washington
[object Object]
STRUCTURAL: High regulatory density (85) due to 8 healthcare bills with impact_ratios 0.0012-0.0013, but no lobbying spend ($0) or donations. EVIDENTIARY: Executive branch holding by Donald J. Trump ($1,001-$15,000) and active congressional trading by 3 members (12 trades total) with mixed buy/sell patterns. Net: Structural regulatory exposure offset by lack of direct influence efforts, evidentiary signals are mixed.
Regulatory ExposureThreats & opportunities
Regulatory threats
-
Increased regulatory scrutiny on clinical trial design and data integrityFDA"Recent bill_impacts array shows 8 healthcare bills with impact_ratios 0.0012-0.0013, indicating legislative focus on sector"
-
Potential changes to drug pricing or reimbursement affecting sponsor budgetsCMS"Recent bill_impacts array shows multiple healthcare bills with estimated revenue impacts ~$15-16M"
Regulatory opportunities
-
Accelerated approval pathways for certain drug classes could increase CRO demandFDA"Recent bill_impacts array shows legislative activity in healthcare sector, potential for pro-innovation bills"
-
Government funding for biomedical research could boost clinical trial volumeNIH"Recent bill_impacts array shows healthcare bills with positive revenue impact estimates"
Capitol Hill AlliesChampions & critics
Congressional champions
Congressional critics
Live signals + predictions for MEDP — for Founders
The free page above gives you the public record. Members see the real-time intelligence layer on top of it:
- Live 7-layer signal scores when Congress trades MEDP
- Bill Pass Index v2 odds for every bill on the watch list
- Iron Triangle alerts (committee × donor × trade)
- SEC Form 4 cluster detection (CEO + CFO + director buys)
- Whale-Opportunity expected-value ranking
- Custom watchlist alerts via email + Discord